Nouscom Poster presentation at ESMO 2021
Nouscom Poster presentation at ESMO 2021, reporting the first clinical dataset from the Phase 1 trial of NOUS-209, an off-the-shelf cancer vaccine based on shared neoantigens, in combination with [...]
Nouscom Poster presentation at ESMO 2021, reporting the first clinical dataset from the Phase 1 trial of NOUS-209, an off-the-shelf cancer vaccine based on shared neoantigens, in combination with [...]
Our head of Preclinical and Clinical Immunology Anna Morena D’alise will join as Expert Speaker at the Next Generation Cancer Vaccine Development Summit from September 7 – 9, 2021. You can [...]
Nouscom will join & present at the SITC 2019 from November 6-10.
Find out the full program here: https://www.terrapinn.com/conference/world-vaccine-congress-europe/agenda.stm
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.